C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-104.99	-105.32	-128.18	-83.89	-66.34
Depreciation & Amortization	1.96	1.82	1.68	1.49	1.62
Stock-Based Compensation	19.1	29.66	30.02	21.51	3.43
Other Adjustments	14.52	1.03	7.32	4.01	7.21
Change in Receivables	0.7	8.7	4.24	-1.23	0.14
Changes in Accounts Payable	-0.47	-0.12	-3.33	-1.18	0.47
Changes in Accrued Expenses	-6.05	-1.27	5.08	4.38	2.56
Changes in Unearned Revenue	-18.84	9.88	-22.65	-25.05	-12.2
Changes in Other Operating Activities	-4.63	-9.55	-0.12	-7	-4.14
Operating Cash Flow	-98.69	-65.16	-105.94	-86.97	-67.25
Capital Expenditures	-0.61	-0.18	-5.5	-1.28	-0.65
Purchases of Investments	-227.07	-284.32	-219.53	-537.74	-293.86
Proceeds from Sale of Investments	219.08	233.23	283.45	349.68	104
Investing Cash Flow	-8.6	-51.27	58.42	-189.34	-190.51
Long-Term Debt Issued	-	-	-	-	11.97
Net Long-Term Debt Issued (Repaid)	-	-	-	-	11.97
Issuance of Common Stock	126.32	45.15	0.78	171.8	195.96
Repurchase of Common Stock	-0.19	-0.19	-	-	-0.76
Net Common Stock Issued (Repurchased)	126.13	44.95	0.78	171.8	195.2
Issuance of Preferred Stock	-	-	-	-	145.53
Net Preferred Stock Issued (Repurchased)	-	-	-	-	145.53
Other Financing Activities	0.27	0.38	0.37	-0.4	-3.61
Financing Cash Flow	126.4	45.34	1.15	171.4	348.93
Net Cash Flow	19.1	-71.09	-46.37	-104.9	91.18
Free Cash Flow	-99.3	-65.34	-111.44	-88.24	-67.9
FCF Margin	-276.24%	-183.61%	-358.36%	-192.73%	-204.55%
Free Cash Flow Per Share	-1.20	-0.94	-2.28	-1.92	-5.97
Levered Free Cash Flow	-133.63	-104.73	-153.02	-112.54	-66.71
Unlevered Free Cash Flow	-143.85	-119.03	-154.38	-110.78	-72.23

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q